Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMD -0.91%72 14-Day RSI is 51.24 as of Jul. 15, 2026. GuruFocus rates BTMD with a GF Score™ of 72/100 and a GF Value™ of $3.07 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 698 Healthcare Providers & Services companies, Biote ranks worse than 54.3% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-15), Biote's 14-Day RSI is 51.24.
The industry rank for Biote's 14-Day RSI or its related term are showing as below:
BTMD's 14-Day RSI is ranked worse than 54.3% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 49.795
vs BTMD: 51.24
Biote (NAS:BTMD) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Biote 14-Day RSI Related Terms
BTMD vs DCGO, PIII, EHSI: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, Biote's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Biote's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMD) has a 14-Day RSI of 51.24 as of Jul. 15, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #379 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 54.3%.
Is Biote's 14-Day RSI too high?
Biote's current 14-Day RSI is 51.24. The Healthcare Providers & Services industry median 14-Day RSI is 49.80. Biote's value of 51.24 is 2.9% above this industry median. Based on the distribution chart, Biote ranks #379 out of 698 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Biote has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's 14-Day RSI compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #379 out of 698 companies for 14-Day RSI. This places Biote in the lower half of its industry. The industry median 14-Day RSI is 49.80. Biote's value of 51.24 is 2.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 49.80, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biote's current 14-Day RSI of 51.24 is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 49.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current 14-Day RSI is 51.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.17 — trading 29.3% below its estimated fair value. The current 14-Day RSI is 51.24 and 2.9% above the Healthcare Providers & Services industry median of 49.80. Biote's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Biote (BTMD), the current 14-Day RSI is 51.24 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $2.17 is trading 29.3% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Modestly Undervalued.
Key valuation signals for BTMD:
14-Day RSI: 51.24
GF Value™: $3.07 vs. price of $2.17 (29.3% below fair value)
Industry Position: 2.9% above the Healthcare Providers & Services median (#379 of 698)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
72GF Score
Get the complete analysis for BTMD
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
